Journal: PLOS Pathogens

Article Title: EBV infection outcomes determined by monocyte and T REG -driven immune dynamics in an ex vivo pbmc model

doi: 10.1371/journal.ppat.1013746

Figure Lengend Snippet: (A) UMAP of single-cell transcriptomes from all donors and conditions, annotated by major immune cell types. (B) UMAP plots and pie charts showing relative frequencies of immune lineages across mock and EBV-infected conditions. (C) Bar plot showing the change in cell type proportions (Δ = EBV – Mock) for each donor, grouped by LCL outcome (n = 2). (D) Subset analysis of CD4 ⁺ T cells showing relative frequencies of Treg and naive CD4 ⁺ cells per donor and condition. (E) Quantification of gp350 ⁺ B cells at Day 7 post-infection in LCL-made and LCL-failed donors PBMCs treated with IgG1 isotype control (Mock), EBV + IgG1 isotype control or EBV + RG6292. Bars represent the number of gp350 ⁺ cells within the CD19 ⁺ B cell compartment (mean ± SEM; p < 0.05, ns = not significant; a paired two-sided Student’s t-test (n = 3)). (F) Representative flow cytometry plot of CD23 and CD20 expression on CD19 ⁺ B cells at Day 21 post-infection. Red and light blue represent EBV-infected cultures treated with isotype control or RG6292, respectively. Marginal histograms show marker intensity distribution. (G) gp350 surface expression on CD19 ⁺ B cells at Day 21 post-infection. Histogram overlay compares isotype- (red) and RG6292-treated (light blue) conditions.

Article Snippet: An equivalent concentration of human IgG1 isotype control (MedChemExpress, Cat# HY-P99001) was used in control conditions (Mock and EBV).

Techniques: Single Cell, Infection, Control, Flow Cytometry, Expressing, Marker

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells.

doi: 10.4049/jimmunol.176.3.1889

Figure Lengend Snippet: FIGURE 7. Abs to IL-1 or IL-6 do not inhibit chemokine secretion in response to TWEAK. C57BL/6 mesangial cells were stimulated for 24 h with and without 100 ng/ml TWEAK and 5 g/ml monoclonal rat anti- mouse IL-1 and IL-6. Rat IgG is an IgG2b mAb that was the rat isotype- matched control. A, CCL2/MCP-1; B, CCL5/RANTES; C, CXCL1/KC. Shown here are the mean SD values for duplicate wells; similar results were found in several independent experiments.

Article Snippet: We found that there was significant binding to the surface of murine mesangial cells by hFc-TWEAK (Fig. 1B), but not by a CTLA4-Ig control fusion protein (R&D Systems) or a human IgG1 mAb (PHP010; Serotec), which share the same IgG1 Fc as hFc-TWEAK (data not shown).

Techniques: Control

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells.

doi: 10.4049/jimmunol.176.3.1889

Figure Lengend Snippet: FIGURE 9. Murine anti-TWEAK mAbs prevent the induction of che- mokines in response to TWEAK stimulation of mesangial cells. The 2.P5.G9 and 2P2.D10 are two IgG2a mouse mAbs against murine TWEAK, derived by immunization of TWEAK knockout mice, as de- scribed in Materials and Methods. P1.17 is an isotype-matched control Ab. C57BL/6 mesangial cells were left untreated, or treated with TWEAK with and without these mAbs at a concentration of 5 g/ml for 24 h. Shown here are the mean SD values for duplicate wells; similar results were found in several independent experiments.

Article Snippet: We found that there was significant binding to the surface of murine mesangial cells by hFc-TWEAK (Fig. 1B), but not by a CTLA4-Ig control fusion protein (R&D Systems) or a human IgG1 mAb (PHP010; Serotec), which share the same IgG1 Fc as hFc-TWEAK (data not shown).

Techniques: Derivative Assay, Knock-Out, Control, Concentration Assay

Journal: Scientific Reports

Article Title: In vitro complement activation via nucleocapsid and spike proteins of SARS-CoV-2 in COVID-19 patients

doi: 10.1038/s41598-025-20926-6

Figure Lengend Snippet: Comparison of the in vitro C3b and C4b complement depositions via spike (C3b(S) and C4b(S)) or nucleocapsid (C3b(N) and C4b(N)) recombinant proteins between patients with (Ab(+)) or without (Ab(-)) SARS-CoV-2-specific IgM and IgG antibodies from four different COVID-19 groups (CONV, HOSP, HOSP + O 2 and ICU). The in vitro C3b and C4b complement depositions were measured by our in-house complement deposition assays, where we used carrier free recombinant nucleocapsid or spike proteins and non-heat-inactivated patient sera. The p values for the pair-wise group comparisons on the violin plots were calculated by the Mann-Whitney tests. P values of significant differences are marked as p MW between without and with specific antibodies. Non-significant differences are marked as n.s.

Article Snippet: Mouse anti-human IgG1 Fc-HRP (HP6001) , SouthernBiotech , 9054-05.

Techniques: Comparison, In Vitro, Recombinant, MANN-WHITNEY

Journal: Scientific Reports

Article Title: In vitro complement activation via nucleocapsid and spike proteins of SARS-CoV-2 in COVID-19 patients

doi: 10.1038/s41598-025-20926-6

Figure Lengend Snippet: Comparison of the levels of SARS-CoV-2-specific IgM and IgG among four COVID-19 groups (CONV, HOSP, HOSP + O2, ICU) measured by Generic Assays CoV-2 IgM or IgG ( a ). The percentages of SARS-CoV-2-specific IgG or IgM positivity were shown also for four different COVID-19 groups. The numbers represent the mean percentages of SARS-CoV-2-specific IgM in blue or specific IgG in green circle sectors ( b ). The levels of total S- or N-specific IgG were quantified by in-house ELISA, normalized to positive and negative serum samples ( c ). The levels of S-specific and N-specific IgG1 ( d ) and IgG3 ( e ) subclasses were quantified by in-house ELISA calibrated with purified human IgG1 and IgG3. The p -values ( p KW ) were determined by Kruskal-Wallis test.

Article Snippet: Mouse anti-human IgG1 Fc-HRP (HP6001) , SouthernBiotech , 9054-05.

Techniques: Comparison, Enzyme-linked Immunosorbent Assay, Purification

Journal: Scientific Reports

Article Title: In vitro complement activation via nucleocapsid and spike proteins of SARS-CoV-2 in COVID-19 patients

doi: 10.1038/s41598-025-20926-6

Figure Lengend Snippet: The in vitro C3b and C4b complement depositions via spike (C3b(S) and C4b(S)) recombinant protein are plotted by the levels of S-specific IgG1 and IgG3 in CONV individuals and in the other three hospitalized COVID-19 groups (HOSP, HOSP + O 2 and ICU) ( a ). The in vitro C3b and C4b complement depositions via nucleocapsid (C3b(N) and C4b(N)) recombinant protein are plotted by the levels of N-specific IgG1 and IgG3 in CONV individuals and in the other three hospitalized COVID-19 groups (HOSP, HOSP + O 2 and ICU) ( b ).

Article Snippet: Mouse anti-human IgG1 Fc-HRP (HP6001) , SouthernBiotech , 9054-05.

Techniques: In Vitro, Recombinant

Journal: Scientific Reports

Article Title: In vitro complement activation via nucleocapsid and spike proteins of SARS-CoV-2 in COVID-19 patients

doi: 10.1038/s41598-025-20926-6

Figure Lengend Snippet: Comparison of the levels of SARS-CoV-2-specific IgM and IgG antibodies, and in vivo complement profiles in all COVID-19 patients between low and high in vitro C3b(N) complement depositions. The p values for the pair-wise group comparisons on the violin plots were calculated by the Mann-Whitney tests. Asterisks indicate p value < 0.0143 , considered significant results after 5% FDR correction using the Benjamini-Hochberg method.

Article Snippet: Mouse anti-human IgG1 Fc-HRP (HP6001) , SouthernBiotech , 9054-05.

Techniques: Comparison, In Vivo, In Vitro, MANN-WHITNEY

Journal: PLOS ONE

Article Title: Crystalline silica-exposed human lung epithelial cells presented enhanced anchorage-independent growth with upregulated expression of BRD4 and EZH2 in autocrine and paracrine manners

doi: 10.1371/journal.pone.0285354

Figure Lengend Snippet: (A) ELISA of EGF, TNF-α, IL-6, and TGF-β1 was performed with the culture supernatants of nonadherent NL20, BEAS-2B, and 16HBE 4–6 days after incubation with autocrine CS or BPDE CM compared with the autocrine control CM. ELISA of EGF, TNF-α, and IL-6 was also conducted with the culture supernatants 48 h after exposure to CS in adherent bronchial cell lines. Asterisks indicate a significant difference in concentration (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (B) Anchorage-independent growth of NL20, BEAS-2B, and 16HBE cells was measured using MTT 5–6 days after the administration of recombinant human EGF, TNF-α, and IL-6. The MTT assay was performed for autocrine CS CM-incubated nonadherent NL20 and BEAS-2B cells four and five days after EGF-neutralizing antibody (NtAb) treatment, respectively, and for autocrine CS CM-incubated nonadherent 16HBE cells, five days after TNF-α NtAb treatment. The MTT assay was also performed for autocrine CS CM-incubated nonadherent bronchial cell lines five days after IL-6 NtAb administration. Asterisks indicate a significant difference in growth (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (C) Expression of BRD4 and EZH2 in nonadherent 16HBE cells three days after the administration of recombinant human TNF-α determined using western blotting and the expression of BRD4 and EZH2 3–4 days after treatment of nonadherent NL20 and BEAS-2B cells with recombinant human EGF.

Article Snippet: Mouse anti-human EGF neutralizing antibody (NtAb), goat anti-human TNF-α NtAb, and mouse anti-human IL-6 NtAb were obtained from R&D Systems.

Techniques: Enzyme-linked Immunosorbent Assay, Incubation, Control, Concentration Assay, Recombinant, MTT Assay, Expressing, Western Blot